Revive Therapeutics Ltd (TSE:RVV)
:RVV
Want to see TSE:RVV full AI Analyst Report?
RVV Stock Chart & Stats
C$0.01
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.01
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.08
Previous CloseN/A
Volume2.50K
Average Volume (3M)285.50K
Market Cap
C$14.65M
Enterprise ValueC$15.30M
Total Cash (Recent Filing)C$30.95K
Total Debt (Recent Filing)C$68.18K
Price to Earnings (P/E)―
Beta-1.19
Next Earnings
May 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding418,564,270
10 Day Avg. Volume295,136
30 Day Avg. Volume285,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Absolute DebtVery low reported absolute debt (~$68K) reduces near-term solvency pressure and lowers fixed financing obligations. This durable capital structure feature preserves flexibility for an R&D-focused biotech, making future financing or partnerships less encumbered by leverage.
Reduced Cash Burn Versus Earlier YearsTTM free cash flow and operating cash flow have materially declined versus earlier multi-million outflows, signaling management has cut run-rate spending. A sustained lower burn rate extends runway and improves chances of funding or executing partnerships without immediate dilution.
Focused Clinical-stage Drug Development ModelA clear R&D-focused business model with clinical-stage candidates creates durable optionality: value can be realized via licensing, partnerships, or eventual commercialization. This asset-centric model suits capital-light monetization through collaborations if clinical data supports progression.
Bears Say
No Revenue And Ongoing Net LossesThe absence of product revenue and large trailing net losses indicate the company remains pre-commercial and reliant on external capital. Persisting non-revenue status undermines margin sustainability and heightens execution risk until a candidate reaches commercialization or a monetization event.
Negative Stockholders' Equity And Collapsed AssetsNegative equity and a material decline in reported assets materially weaken the balance sheet, reducing financial flexibility. This structural deterioration increases dependence on dilutive funding or partner deals and raises creditor and investor governance risk over the medium term.
Persistent Cash Burn; Not Self-fundingOngoing negative operating cash flow and free cash flow confirm the business cannot self-fund its clinical programs. Over months, this structural cash gap requires external financing or milestone-based partner funding, which can dilute shareholders or delay programs if market conditions shift.
Revive Therapeutics News
RVV FAQ
What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <C$0.01 and its highest was C$0.08 in the past 12 months.
What is Revive Therapeutics Ltd’s market cap?
Revive Therapeutics Ltd’s market cap is C$14.65M.
When is Revive Therapeutics Ltd’s upcoming earnings report date?
Revive Therapeutics Ltd’s upcoming earnings report date is May 29, 2026 which is in 31 days.
How were Revive Therapeutics Ltd’s earnings last quarter?
Revive Therapeutics Ltd released its earnings results on Feb 27, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is Revive Therapeutics Ltd overvalued?
According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued.
Does Revive Therapeutics Ltd pay dividends?
Revive Therapeutics Ltd does not currently pay dividends.
What is Revive Therapeutics Ltd’s EPS estimate?
Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics Ltd have?
Revive Therapeutics Ltd has 418,564,270 shares outstanding.
What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
Revive Therapeutics Ltd reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 50%.
Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
Currently, no hedge funds are holding shares in TSE:RVV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---